Background: The efficacy of Helicobacter pylori eradication regimens may depend on
clarithromycin, has been a worldwide choice for H. pylori eradication. 5, 9, 10 However, the eradication rate of the conventional triple therapy has decreased in recent years because of the increase in antibiotic resistance. [11] [12] [13] [14] [15] To improve the eradication rate, alternative regimens have been suggested, including sequential, concomitant, and hybrid therapies. [16] [17] [18] Many head-to-head trials were performed to compare H. pylori eradication rates among various regimens, and the relative efficacy of these regimens has been analyzed via pairwise meta-analyses. [19] [20] [21] [22] However, establishment of the optimal regimen is still a challenge because of two major reasons. First, the eradication rate of H. pylori eradication regimens may depend on the country where the studies were performed because of the difference in antibiotic resistance. 23 The estimates based on worldwide trials may be limited to guide clinicians to select optimal regimens. Therefore, the results of the studies conducted in the same region need to be summarized for understanding the efficacy of various eradication regimens in a given country.
Second, traditional pairwise meta-analysis is difficult to integrate and cannot systematically compare more than two eradication regimens.
Indirect estimates from studies comparing treatments of interest with a common comparator should be considered for analyzing the relative efficacy of multiple treatment regimens. 24 Previous meta-analyses reported inconsistent results of comparative efficacy among the eradication regimens. 19, 20 For example, a previous meta-analysis for Asian studies showed that the sequential therapy was superior in terms of eradication to the conventional triple therapy. 20 However, the Cochrane review published in 2016 demonstrated that recent studies did not show different eradication rate between the sequential and conventional triple therapies. 19 Such a discrepancy may be due to the geographic distribution of antibiotic resistance, especially for clarithromycin. 23 In Korea, clarithromycin resistance rate remained high in recent 
| METHODS
This systematic review and network meta-analysis were conducted according to the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) statement 25 and the report of the International Society for Pharmacoeconomics and Outcomes
Research Task Force on Indirect Treatment Comparisons Good
Research Practices. 24 
| Search strategy
We searched for all relevant studies published between January 1990
and November 2016 that investigated the efficacy of H. pylori eradication therapies using MEDLINE, EMBASE, the Cochrane Library, and
KoreaMed databases. The following search string was used ((helicobacter) OR (campylobacter) OR (pylori*)) AND ((eradication) OR (treatment)) AND (korea*). The detailed search strategies for each database are shown in Appendix 1. To identify additional studies, we also examined the references of the screened articles. The latest date for updating our search was November 30, 2016.
| Study selection
In the first step for study selection, the titles and abstracts of articles retrieved by our keyword search were examined to exclude the irrelevant articles. Next, the full text of all the selected studies was screened according to our inclusion and exclusion criteria. The primary end point of this meta-analysis was the pooled eradication rate in the ITT analysis. The secondary end point was the comparative efficacy in terms of H. pylori eradication rate and the tolerability.
| Statistical analysis
Meta-analysis was conducted to calculate the pooled eradication rate with 95% confidence interval (CI) for each eradication regimen using a random effects model. A frequentist network meta-analysis was performed to calculate the direct and indirect estimates and to combine the mixed estimates. 27 If no event (or nonevent) was observed in 
| RESULTS

| Study selection
A flow diagram for our systematic review is shown in Figure 1 . A total of 2236 studies were identified by our literature search. After scanning the titles and abstracts, we discarded 731 duplicate articles, which were retrieved through multiple search engines. Another 1447 irrelevant articles were excluded based on the titles and abstracts.
After the full texts of the 58 remaining articles were reviewed, 15
were excluded because of the following reasons: (i) two nonoriginal studies, (ii) six retrospective studies, (iii) six studies with uncertain study design, and (iv) one duplicate publication in a non-English language journal. As a result, the remaining 43 studies were included in our systematic review and qualitative synthesis. Among them, nine studies published before 2005 were excluded from the quantitative synthesis. [34] [35] [36] [37] [38] [39] [40] [41] [42] Finally, 34 studies were included in the network meta-analysis.
43-76
| Study characteristics and risk of bias assessment
The study characteristics and detailed information about H. pylori eradication regimens are shown in Tables 1 and S1 , respectively. All studies were published between 1994 and 2017 with an enrollment period that ranged from 1993 to 2015. The latest study published in 2017 was identified through our literature search; it was published online ahead of print on August 9, 2016. 76 Among the 34 studies included in the meta-analysis, four were published in Korean, and 30 studies were published in English. They included 11 332 participants.
Six studies included only patients with peptic ulcer, low-grade gastric MALT lymphoma, or endoscopically resected early gastric cancer, which were the indications covered by the Korean National Health Insurance, whereas the other studies included patients regardless of the indications (ie gastritis, erosion, or dyspepsia).
Overall, the conventional triple therapy for 7 days (TT-7) was the most frequently compared regimen, which was included in 24 studies. Sequential therapy for 10 days (ST-10) was the second most commonly compared regimen, which was included in 14 studies. The network of the 34 studies included in the network meta-analysis is shown in Figure 2 . Quality assessments for individual studies are presented in Fig. S1 . T A B L E 1 (Continued)
| Comparative efficacy of H. pylori eradication regimens
Because TT-7 was the most commonly analyzed regimen in the individual studies, we showed the comparative efficacy of each eradication regimen determined based on the eradication rate of TT-7 through Forest plots (Fig. S3 ). In terms of tolerability, most regimens were comparable to TT-7 ( Quinolone-containing sequential therapy for 10 days (ST-Q-10)
was assessed only in one study published in 2015. 70 In this study, 
| Network heterogeneity and inconsistency
In terms of eradication rate, there was no significant heterogeneity in the whole network (ITT analysis: Cochran's Q=19. Figure 3A shows the P-score of each regimen for the eradication rate in ITT analysis against that for tolerability. The P-score of each eradication regimen can be interpreted as the mean extent of certainty that a certain regimen was better than another one. 32 P-scores of TT-7 were 23.2% and 64.3% for the eradication rate in ITT analysis and tolerability, respectively. Generally, sequential and concomitant therapies showed higher P-scores for eradication rate and lower Pscores for tolerability compared to TT-7 (eradication rate in ITT analysis: ST≥14, 72.5%; ST-10, 65.4%; CT≥10, 81.3%; and CT≤7, 79.9%; tolerability: ST≥14, 49.3%; ST-10, 45.8%; CT≥10, 35.0%; and CT≤7, 48.6%). HT≥10 also showed a higher P-score for eradication rate compared to TT-7 (eradication rate in ITT analysis: 81.4%; tolerability:
| Ranking of different regimens based on eradication rate and tolerability
68.3%). ST-Q-14 showed the highest P-score for eradication rate with a relatively good P-score for tolerability (eradication rate in ITT analysis: 99.8%; tolerability: 55.7%).
In addition, the relation between the P-scores of eradication rate in PP analysis and those of tolerability was similar to that between the P-scores of eradication rate in ITT analysis and those of tolerability, as shown in Figure 3B .
| DISCUSSION
The PPI-clarithromycin-containing triple therapy without prior susceptibility testing should be abandoned in the regions where clarithromycin resistance rate is more than 15%. 78 Our network meta-analysis included the recently published studies after revision of the Korean guidelines. It showed that the conventional triple therapy was inferior to the sequential, hybrid, and concomitant therapies. Although the tolerability of ST-10 and ST≥14
tended to be lower than that of TT-7, it was comparable to that of TT-10 and TT-14. In addition, the tolerability of the hybrid therapy was comparable to that of TT-7, TT-10, and TT-14. Therefore, it might be inappropriate to treat H. pylori infections with TT-10 or TT-14 rather than ST-10, ST≥14, or HT≥10, given that the sequential and hybrid therapies had better eradication rates than and a comparable tolerability to the conventional triple therapy.
In the previous pairwise meta-analysis in Korea, sequential therapy was superior to TT-7 in terms of eradication, while the efficacy did not differ between the sequential therapy vs TT-10 or TT-14. On the other hand, there were several regimens including additive drugs, such as probiotics and mucoprotective agents. These regimens were devised as an effort to improve the efficacy of TT-7.
Unfortunately, they showed a less tolerability than TT-7, the sequential and concomitant therapies. Although TT-7+probiotics was superior to TT-7 in terms of eradication rate, prolonged administration of probiotics for 3-8 weeks may be a drawback of the probiotic-containing regimens.
In addition, our study showed the trend of the studies on H. pylori eradication during the last 20 years. The conventional triple therapy was the most widely investigated regimen in Korea, and it was con- of the individual studies were designed to compare the regimens of interest with each other; therefore, most of the comparisons had direct estimates. Second, susceptibility testing was not considered in our network meta-analysis. Although susceptibility testing is a strong method for choosing the optimal eradication regimen for each patient, it was not used in most Korean studies. The results of our network meta-analysis should be used only when the eradication therapy will be planned without prior susceptibility testing.
Despite these limitations, our network meta-analysis provides a better understanding of the efficacy of various first-line eradication regimens in Korea. Both sequential and hybrid therapies had a superior efficacy in terms of eradication rate and a comparable tolerability, compared to the results reported for the conventional triple therapies, including TT-7, TT-10, and TT-14. However, they did not achieve 90% of eradication rate in the ITT analysis. Only ST-Q-14 showed an acceptable eradication rate with a good tolerability among the 21 included regimens in Korea; however, more studies on this regimen are required for reaching a definitive conclusion.
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